

October 31, 2025

The Listing Department
BSE Limited
Phiroze Jeejebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)

In furtherance to our letter dated September 30, 2025, and pursuant to Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company, at their meeting held today i.e., October 31, 2025 approved the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025 along with Limited Review Report received from the Statutory Auditors of the Company.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Limited Review Report received from B S R and Co, the Statutory Auditors of the Company along with Un-audited Standalone and Consolidated Financial Results is enclosed herewith.

The meeting commenced at 02:00 PM and concluded at 03:45 PM.

The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.

Kindly take note of the same.

For MedPlus Health Services Limited


Manoj Kumar Srivastava
Company Secretary & Compliance Officer



Encl: a/a

31/10/2025

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Limited Review Report (Continued)

MedPlus Health Services Limited

6. We did not review the interim financial results of two subsidiaries included in the Statement, whose interim financial results reflect total assets (before consolidation adjustments) of Rs. 1,284.61 million as at 30 September 2025 and total revenues (before consolidation adjustments) of Rs. 1,855.75 million and Rs. 3,458.85 million, total net profit after tax (before consolidation adjustments) of Rs. 10.93 million and Rs. 20.52 million and total comprehensive income (before consolidation adjustments) of Rs. 10.93 million and Rs. 20.52 million, for the quarter ended 30 September 2025 and for the period from 1 April 2025 to 30 September 2025 respectively, and cash flows (net) (before consolidation adjustments) of Rs 27.44 million for the period from 1 April 2025 to 30 September 2025. as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial results of eight subsidiaries which have not been reviewed, whose interim financial results reflect total assets (before consolidation adjustments) of Rs. 813.14 million as at 30 September 2025 and total revenues (before consolidation adjustments) of Rs. 653.61 million and Rs. 1,259.30 million, total net profit after tax (before consolidation adjustments) of Rs. 9.09 million and Rs. 15.16 million and total comprehensive income (before consolidation adjustments) of Rs. 9.09 million and Rs. 15.16 million, for the quarter ended 30 September 2025 and for the period from 1 April 2025 to 30 September 2025 respectively, and cash flows (net) (before consolidation adjustments) of Rs 8.80 million for the period from 1 April 2025 to 30 September 2025. as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R and Co

Chartered Accountants

Firm's Registration No.:128510W



Arpan Jain

Partner

Hyderabad

31 October 2025

Membership No.: 125710

UDIN:25125710BMOXYY8283

Limited Review Report (Continued)
MedPlus Health Services Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	MedPlus Health Services Limited	Holding Company
2	Optival Health Solutions Private Limited	Subsidiary
3	Nova Sud Pharmaceuticals Private Limited	Subsidiary
4	Wynclark Pharmaceuticals Private Limited	Subsidiary
5	Kalyani Meditimes Private Limited	Subsidiary
6	Clearancekart Private Limited	Subsidiary
7	Sai Sridhar Pharma Private Limited	Subsidiary
8	Venkata Krishna Enterprises Private Limited	Subsidiary
9	Shri Banashankari Pharma Private Limited	Subsidiary
10	Deccan Medisales Private Limited	Subsidiary
11	Sidson Pharma Distributors Private Limited	Subsidiary
12	MedPlus Insurance Brokers Private Limited	Subsidiary

17

MedPlus Health Services Limited

CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037
Statement of Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2025

(Rs. in Millions)

S. No.	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	16,793.29	15,426.34	15,761.72	32,219.63	30,649.97	61,360.53
	Other income	174.69	150.19	115.96	324.88	203.08	486.16
I	Total income	16,967.98	15,576.53	15,877.68	32,544.51	30,853.05	61,846.69
	Expenses						
	Cost of materials consumed	234.06	191.80	155.54	425.86	279.32	617.19
	Purchases of stock-in-trade	12,208.98	10,529.48	10,830.09	22,738.46	23,288.52	45,724.81
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(40.53)	676.08	1,033.11	635.55	46.59	64.61
	Employee benefits expense	2,133.22	2,004.41	1,803.42	4,137.63	3,421.64	7,260.17
	Finance costs	288.19	273.65	251.16	561.84	497.74	1,025.86
	Depreciation and amortisation expense	685.62	656.18	631.35	1,341.80	1,231.65	2,498.43
	Other expenses	769.09	717.27	695.17	1,486.36	1,431.88	2,822.73
II	Total expenses	16,278.63	15,048.87	15,399.84	31,327.50	30,197.34	60,013.80
III	Profit before tax (I-II)	689.35	527.66	477.84	1,217.01	655.71	1,832.89
	Tax expense						
	- Current tax expense	202.30	143.92	136.97	346.22	197.41	479.49
	- Deferred tax benefit	(67.97)	(39.69)	(46.12)	(107.66)	(72.13)	(148.93)
IV	Total tax expense	134.33	104.23	90.85	238.56	125.28	330.56
V	Net Profit after tax (III-IV)	555.02	423.43	386.99	978.45	530.43	1,502.33
	Other comprehensive income (OCI)						
	(i) Items that will not be reclassified to profit or loss						
	- Re-measurement gain on employee defined benefit plan	-	-	-	-	-	2.02
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(0.56)
VI	Other comprehensive income for the period/year, net of tax	-	-	-	-	-	1.46
VII	Total comprehensive income for the period/year (V+VI)	555.02	423.43	386.99	978.45	530.43	1,503.79
VIII	Profit for the period/year attributable to:						
	Shareholders of the Company	555.01	423.58	387.36	978.59	530.99	1,503.22
	Non-controlling interest	0.01	(0.15)	(0.37)	(0.14)	(0.56)	(0.89)
		555.02	423.43	386.99	978.45	530.43	1,502.33
IX	Total comprehensive income attributable to:						
	Shareholders of the Company	555.01	423.58	387.36	978.59	530.99	1,504.68
	Non-controlling interest	0.01	(0.15)	(0.37)	(0.14)	(0.56)	(0.89)
		555.02	423.43	386.99	978.45	530.43	1,503.79
X	Paid-up Capital						
	Equity Share Capital	239.64	239.49	239.09	239.64	239.09	239.39
XI	Other Equity						17,166.22
XII	Earnings per equity share (refer note 3)						
	Basic EPS (In absolute Rs)	4.63	3.54	3.24	8.17	4.44	12.57
	Diluted EPS (In absolute Rs)	4.62	3.53	3.23	8.15	4.42	12.52
XIII	Face value per share						
	Equity shares (In absolute Rs)	2.00	2.00	2.00	2.00	2.00	2.00



(Handwritten marks)

Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter and Half year ended September 30, 2025

(Rs. In Millions)

Particulars	Quarter Ended			Half year ended		Year Ended
	September 30 2025	June 30, 2025	September 30 2024	September 30 2025	September 30 2024	March 31, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment revenue						
a. Retail	16,456.41	15,121.19	15,474.83	31,577.60	30,118.41	60,268.86
b. Diagnostic services	332.50	302.90	283.14	635.40	525.57	1,081.07
c. Others	4.38	2.25	3.75	6.63	5.99	10.60
Total revenue from operations	16,793.29	15,426.34	15,761.72	32,219.63	30,649.97	61,360.53
2. Segment results profit / (loss)						
a. Retail	592.04	449.54	476.23	1,041.58	671.52	1,759.71
b. Diagnostic services	2.07	0.77	(33.28)	2.84	(76.18)	(109.76)
c. Others	3.09	1.07	2.28	4.16	2.94	4.89
Total	597.20	451.38	445.23	1,048.58	598.28	1,654.84
Add/(Less): Unallocable Finance cost	0.16	(0.27)	-	(0.11)	-	(0.59)
Add: Unallocable other income	91.99	76.55	32.61	168.54	57.43	178.64
Total profit before tax	689.35	527.66	477.84	1,217.01	655.71	1,832.89
3. Segment assets						
a. Retail	27,327.68	26,783.08	26,222.92	27,327.68	26,222.92	26,994.85
b. Diagnostic services	1,437.41	1,427.40	1,518.89	1,437.41	1,518.89	1,444.98
c. Others	5.38	5.93	-	5.38	-	7.77
d. Unallocated	6,951.69	6,284.53	3,808.87	6,951.69	3,808.87	5,153.35
Total assets	35,722.16	34,500.94	31,550.68	35,722.16	31,550.68	33,600.95
4. Segment liabilities						
a. Retail	16,261.06	15,669.74	14,210.48	16,261.06	14,210.48	15,289.58
b. Diagnostic services	1,016.67	983.75	977.91	1,016.67	977.91	911.18
c. Others	1.19	1.57	5.57	1.19	5.57	1.20
Total liabilities	17,278.92	16,655.06	15,193.96	17,278.92	15,193.96	16,201.96



Handwritten signature in blue ink.

Handwritten initials in blue ink.

Unaudited Consolidated Balance sheet as at September 30, 2025

(Rs. in Millions)

S.No.	Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
I	ASSETS		
	Non-current assets		
	Property, plant and equipment	2,905.18	2,906.71
	Capital work-in-progress	173.31	131.76
	Goodwill	414.51	414.51
	Other intangible assets	80.72	63.46
	Intangible assets under development	11.63	30.98
	Right-of-use assets	10,140.95	9,579.05
	Financial assets		
	Loans	-	-
	Trade receivables	-	-
	Other financial assets	1,106.19	920.80
	Deferred tax assets (net)	1,105.96	998.28
	Other tax assets (net)	96.77	101.50
	Other non-current assets	36.56	18.74
		16,071.78	15,165.79
	Current assets		
	Inventories	12,807.39	13,450.99
	Financial assets		
	Trade receivables	180.88	132.71
	Cash and cash equivalents	2,097.80	860.52
	Bank balances other than cash and cash equivalents	2,921.26	2,811.66
	Other financial assets	1,026.41	814.10
	Current tax assets (net)	-	0.43
	Other current assets	616.64	364.75
		19,650.38	18,435.16
	Total Assets	35,722.16	33,600.95
	EQUITY AND LIABILITIES		
II	Equity		
	Equity share capital	239.64	239.39
	Other equity	18,210.36	17,166.22
	Total equity attributable to the owners of the Company	18,450.00	17,405.61
	Non-controlling interest	(6.76)	(6.62)
	Total Equity	18,443.24	17,398.99
III	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Lease liabilities	10,104.56	10,080.14
	Other financial liabilities	4.58	4.58
	Provisions	400.34	351.30
		10,509.48	10,436.02
	Current liabilities		
	Financial liabilities		
	Borrowings	-	-
	Lease liabilities	1,826.18	1,117.88
	Trade payables		
	- Total outstanding dues of micro and small enterprises	115.99	163.92
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	3,277.45	2,825.67
	Other financial liabilities	624.77	833.87
	Other current liabilities	213.58	200.09
	Contract liabilities	320.58	260.56
	Provisions	368.70	360.97
	Current tax liabilities (net)	22.19	2.98
		6,769.44	5,765.94
	Total Liabilities	17,278.92	16,201.96
	Total Equity and Liabilities	35,722.16	33,600.95



②

Notes to the Unaudited consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('the Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on October 31, 2025. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from December 23, 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:


(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to September 30, 2025	Unutilised amount as on September 30, 2025*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,117.63	694.13	423.50
Total	5,789.33	5365.83	423.50

* The aforesaid unutilised proceeds of Rs. 423.50 million have been placed as fixed deposits with bank.

3. The earnings per equity share for the quarters and half year ended are not annualised.
4. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited


G. Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097

Place: Hyderabad
Date: October 31, 2025



Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")).
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

10

B S R and Co

Limited Review Report (Continued)
MedPlus Health Services Limited

contains any material misstatement.

For **B S R and Co**
Chartered Accountants
Firm's Registration No.:128510W



Arpan Jain
Partner

Hyderabad
31 October 2025

Membership No.: 125710
UDIN:25125710BMOXYZ4191

MedPlus Health Services Limited
CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037

Statement of Unaudited Standalone Financial Results for the Quarter and Half year ended September 30, 2025

(Rs. in Millions)

S. No	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	2,056.48	1,838.81	1,562.26	3,895.29	3,345.52	7,130.97
	Other income	29.38	26.45	22.50	55.83	40.95	89.35
I	Total income	2,085.86	1,865.26	1,584.76	3,951.12	3,386.47	7,220.32
	Expenses						
	Cost of materials consumed	234.06	191.80	154.52	425.86	278.29	616.18
	Purchases of stock-in-trade	1,314.07	1,175.20	1,010.55	2,489.27	2,275.79	4,860.25
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3.75)	4.98	(0.77)	1.23	1.37	(10.90)
	Employee benefits expense	132.61	122.64	118.35	255.25	230.82	472.20
	Finance costs	23.70	21.52	20.88	45.22	41.94	86.25
	Depreciation and amortisation expense	70.37	67.21	74.66	137.58	139.25	269.37
	Other expenses	108.67	105.13	110.16	213.80	206.71	415.25
II	Total expenses	1,879.73	1,688.48	1,488.35	3,568.21	3,174.17	6,708.60
III	Profit before tax (I-II)	206.13	176.78	96.41	382.91	212.30	511.72
	Tax expense						
	- Current tax expense	53.79	46.91	16.48	100.70	45.16	109.22
	- Deferred tax (benefit) / expense	(3.97)	(5.46)	2.46	(9.43)	(2.69)	(0.85)
IV	Total tax expense	49.82	41.45	18.94	91.27	42.47	108.37
V	Net Profit after tax (III-IV)	156.31	135.33	77.47	291.64	169.83	403.35
	Other comprehensive income (OCI)						
	(i) Items that will not be reclassified to profit or loss						
	Re-measurement gain on employee defined benefit plan	-	-	-	-	-	2.67
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(0.67)
VI	Other comprehensive income for the period / year, net of tax	-	-	-	-	-	2.00
VII	Total comprehensive income for the period / year (V+VI)	156.31	135.33	77.47	291.64	169.83	405.35
VIII	Paid-up capital						
	Equity share capital	239.64	239.49	239.09	239.64	239.09	239.39
IX	Other Equity						12,164.08
X	Earnings per equity share (refer note 4)						
	Basic EPS (In absolute Rs)	1.31	1.13	0.65	2.44	1.42	3.37
	Diluted EPS (In absolute Rs)	1.30	1.13	0.65	2.43	1.42	3.36
XI	Face value per share						
	Equity shares (In absolute Rs)	2.00	2.00	2.00	2.00	2.00	2.00



[Handwritten signature]

[Handwritten signature]

MedPlus Health Services Limited
CIN - L85110TG2006PLC051845
Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally,
Hyderabad 500037

Unaudited Standalone Balance sheet as at September 30, 2025

(Rs. in Millions)

S.No.	Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
I	ASSETS		
	Non-current assets		
	Property, plant and equipment	963.91	1,007.21
	Capital work-in-progress	10.51	12.29
	Other intangible assets	13.38	17.57
	Right-of-use assets	865.73	814.80
	Financial assets		
	Investments	9,300.21	9,282.31
	Other financial assets	136.27	53.75
	Deferred tax assets (net)	45.40	35.97
	Other tax assets (net)	10.88	17.03
	Other non-current assets	0.85	0.85
		11,347.14	11,241.78
	Current assets		
	Inventories	177.52	183.23
	Financial assets		
	Trade receivables	1,271.85	1,216.21
	Cash and cash equivalents	179.41	113.00
	Bank balances other than cash and cash equivalents	565.84	457.22
	Other financial assets	593.49	688.77
	Other current assets	161.26	94.29
		2,949.37	2,752.72
	Total Assets	14,296.51	13,994.50
	EQUITY AND LIABILITIES		
II	Equity		
	Equity share capital	239.64	239.39
	Other equity	12,521.23	12,164.08
	Total Equity	12,760.87	12,403.47
III	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Lease liabilities	868.98	886.41
	Provisions	20.52	16.66
		889.50	903.07
	Current liabilities		
	Financial liabilities		
	Lease liabilities	143.85	58.69
	Trade payables		
	- Total outstanding dues of micro and small enterprises	38.91	28.91
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	277.48	422.74
	Other financial liabilities	34.66	37.89
	Other current liabilities	32.21	33.89
	Contract liabilities	93.44	82.74
	Provisions	25.59	23.10
		646.14	687.96
	Total Liabilities	1,535.64	1,591.03
	Total Equity and Liabilities	14,296.51	13,994.50



Handwritten signature in blue ink.

Handwritten initials in blue ink.

MedPlus Health Services Limited
CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad
500037

Unaudited Standalone Cash Flow Statement for the Half year ended September 30, 2025

(Rs. in Millions)

S.No.	Particulars	For the Half year ended September 30, 2025 (Unaudited)	For the Half year ended September 30, 2024 (Unaudited)
I	Cash flow from operating activities		
	Profit before tax	382.91	212.30
	Adjustments for:		
	Depreciation of property, plant and equipment and Amortisation of intangible assets	79.72	87.68
	Depreciation of right-of-use assets	57.87	51.57
	Provision for gratuity and leave benefits	10.80	8.98
	Loss allowance on doubtful debts	-	0.61
	Advances/debts written off	0.07	0.02
	Interest on lease liabilities	45.22	41.94
	Interest income	(43.69)	(29.89)
	Liabilities no longer required written back	0.17	(0.51)
	Gain on de-recognition of right-of-use assets	(3.74)	(1.85)
	Employees stock option compensation expenses	3.58	6.20
	Operating profit before working capital changes	532.91	377.05
	Changes in assets and liabilities:		
	(Increase)/Decrease in inventories	5.70	(23.13)
	(Increase)/Decrease in non-current financial assets	(4.62)	0.31
	Increase in current financial assets	(43.31)	(386.11)
	Increase in other assets	(67.11)	(7.64)
	Increase/(Decrease) in current financial liabilities	(140.85)	163.17
	Increase/(Decrease) in other current liabilities	9.01	(13.84)
	Decrease in provisions	(4.46)	(2.53)
	Cash generated from operations	287.27	107.28
	Taxes paid (net of refund)	(94.56)	(33.94)
	Net cash generated from operating activities (A)	192.71	73.34
II	Cash flow from investing activities		
	Purchase of property, plant and equipment and intangibles including capital work-in-progress and capital creditors	(28.09)	(55.03)
	Proceeds from sale of property, plant and equipment	-	2.23
	Investment in bank deposits	(941.25)	(1,218.20)
	Proceeds from maturity of bank deposits	841.20	1,412.63
	Interest received	36.88	42.19
	Net cash generated from/(used in) investing activities (B)	(91.26)	183.82
III	Cash flow from financing activities		
	Proceeds from issue of equity shares under employee stock option compensation plan	44.28	8.17
	Interest payment on lease liabilities	(45.22)	(41.94)
	Principal repayment of lease liabilities	(34.10)	(25.72)
	Net cash used in financing activities (C)	(35.04)	(59.49)
	Net increase in cash and cash equivalents (A+B+C)	66.41	197.67
	Cash and cash equivalents at the beginning of the period	113.00	137.20
	Cash and cash equivalents at the end of the period	179.41	334.87
	Components of cash and cash equivalents		
	Cash on hand	0.39	0.88
	Deposits with original maturity of less than three months	162.08	316.84
	Balance in wallets	2.27	2.48
	Balance with banks in current accounts	14.67	14.67
	Total cash and cash equivalents	179.41	334.87



[Handwritten signature]

[Handwritten initials]

Notes to the Unaudited standalone financial results:

1. The above unaudited standalone financial results of MedPlus Health Services Limited ('the Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on October 31, 2025. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from December 23, 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to September 30, 2025	Unutilised amount as on September 30, 2025*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,117.63	694.13	423.50
Total	5,789.33	5,365.83	423.50

* The aforesaid unutilised proceeds of Rs. 423.50 million have been placed as fixed deposits with bank.

3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.
4. The earnings per equity share for the quarters and half year ended are not annualised.
5. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited


G. Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad
Date: October 31, 2025

